What's new

Opinion/decision on a Paediatric investigation plan (PIP): Olumiant, Baricitinib, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Infectious diseases, PIP number: P/0364/2022

Opinion/decision on a Paediatric investigation plan (PIP): Olumiant, Baricitinib, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Infectious diseases, PIP number: P/0364/2022

May 20, 2025 - 16:15
 0
Opinion/decision on a Paediatric investigation plan (PIP): Olumiant, Baricitinib, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Infectious diseases, PIP number: P/0364/2022
Opinion/decision on a Paediatric investigation plan (PIP): Olumiant, Baricitinib, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Infectious diseases, PIP number: P/0364/2022
Read More

Tags:

Previous Article

Human medicines European public assessment report (EPAR): Korjuny, catumaxomab, ...

Next Article

Opinion/decision on a Paediatric investigation plan (PIP): Dupixent, dupilumab, ...

Related Posts

Human medicines European public assessment report (EPAR): Conbriza, bazedoxifene, Date of authorisation: 17/04/2009, Revision: 16, Status: Authorised

Human medicines European public assessment report (EPAR...

May 20, 2025  0

Opinion/decision on a Paediatric investigation plan (PIP): Dupixent, dupilumab, decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), therapeutic area: Dermatology, PIP number: P/0120/2022

Opinion/decision on a Paediatric investigation plan (PI...

May 20, 2025  0

Records of data processing activity for the Organisatio...

May 19, 2025  0